The termination removes the dilutive overhang of a massive equity facility relative to the $7M market cap, which is a modest positive. However, it also eliminates a potential financing backstop for a micro-cap company. Monitor for alternative financing arrangements or cash runway updates in the next quarterly filing.
Price Chart
Executive Summary
DNA X, Inc. terminated its ChEF Purchase Agreement with Chardan Capital Markets, which had committed up to $500 million to purchase shares of the company's common stock. The termination removes a potential future equity financing source, but also eliminates the dilutive overhang from the undrawn facility. No termination fees or financial penalties were disclosed.
Key Facts
- ChEF Purchase Agreement with Chardan Capital Markets, dated September 29, 2025, terminated effective May 28, 2026.
- The agreement had committed up to $500 million of common stock purchases, subject to limitations and conditions.
- Registration Rights Agreement associated with the ChEF Agreement was also terminated.
- No termination fees, penalties, or financial consideration were disclosed in the filing.
- The company's market cap is approximately $7 million, making the $500 million facility highly dilutive if ever utilized.
Financial Impact
Removes a potential $500 million equity financing facility; no immediate cash impact.
Risk Factors
- Loss of a committed equity financing source could constrain liquidity if the company needs capital.
- The company may need to seek alternative, potentially more expensive or dilutive financing.
- No disclosure of the company's current cash position or near-term funding needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027295 |
| Document: 0001493152-26-027295-index-headers.html | 0001493152-26-027295 |
| Document: 0001493152-26-027295-index.html | 0001493152-26-027295 |
| Document: 0001493152-26-027295.txt | 0001493152-26-027295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 8w ago | 8-K | $3.53 $4.57 | ▲ +29.50% | ▲ +29.19% | $2.96 (−16.03%) |
Aug 27, 2026 8w ago | 8-K | $3.27 $4.06 | ▲ +24.16% | ▲ +24.26% | $2.96 (−9.48%) |
Aug 19, 2026 9w ago | Press Release | $3.44 $2.96 | ▲ +13.95% | ▲ +13.95% | $2.96 (+13.95%) |
Jul 2, 2026 16w ago | 8-K | $3.75 $3.25 | ▲ +13.33% | ▲ +12.92% | $2.96 (+21.07%) |
Jun 12, 2026 19w ago | EFFECT | $4.74 $4.05 | ▲ +14.56% | ▲ +16.34% | $2.96 (+37.55%) |
Jun 4, 2026 20w ago | 8-K | $4.75 $4.21 | ▼ −11.37% | ▼ −13.23% | $2.96 (−37.68%) |
May 27, 2026 21w ago | 8-K | $4.24 $5.70 | ▼ −34.43% | ▼ −37.58% | $2.96 (+30.19%) |
Apr 30, 2026 25w ago | 8-K / 10-K/A | $4.89 $4.73 | ▲ +3.27% | ▲ +8.56% | $2.96 (+39.47%) |
Apr 14, 2026 27w ago | 8-K | $3.15 $5.10 | ▲ +61.90% | ▲ +55.86% | $2.96 (−6.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers